Clinical Trial

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-05-25; most recent amendment 2026-01-08.
Trial Details
NCT Number NCT05397639
Lead Sponsor Suven Life Sciences Limited
Conditions Agitation, Alzheimer's Type Dementia
Enrollment 375 participants
Start Date 2022-11-01
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-12